RxDoctor Payments Data

Joanne Gaw, MD

Internal Medicine · Carrollton, GANPI 1417948308

Payments from drug & device makers

$10,761in general payments, 2019–2025

Across 670 payments — averaging $16.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Lilly USA, LLC$966
  • AbbVie$825
  • Amgen$731
  • Otsuka America Pharmaceutical, Inc.$644
  • Pfizer$625
  • plus $5K from 49 others

What the payments were for

  • Food & beverage$10,753100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,761 in reported general payments places this provider in the 90th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$87,536
Medicare patients
140
Services billed
2,573

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide52$48,727
JardianceEmpagliflozin34$45,027
TrulicityDulaglutide22$38,146
MounjaroTirzepatide34$35,466
JanuviaSitagliptin Phosphate30$29,634
EliquisApixaban23$26,225
RexultiBrexpiprazole11$15,842
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$15,414
RybelsusSemaglutide16$15,247
MyrbetriqMirabegron21$12,987
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$9,236
ShingrixVaricella-Zoster Ge/As01b/Pf14$3,082
Atorvastatin Calcium313$1,906
Levothyroxine Sodium157$1,699
Albuterol Sulfate HfaAlbuterol Sulfate64$1,593

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$966$73,61256 claims
Novo NordiskOzempic, Rybelsus$1,563$63,97568 claims
Boehringer IngelheimJardiance$300$45,02734 claims
MerckJanuvia$30$29,63430 claims
PfizerEliquis$625$26,22523 claims
GSKTrelegy Ellipta, Shingrix$366$18,49639 claims
Otsuka America Pharmaceutical, Inc.Rexulti$644$15,84211 claims
Astellas Pharma US IncMyrbetriq$425$12,98721 claims
AstraZenecaBreztri Aerosphere$597$9,23615 claims
AbbVieSynthroid$825$1,30114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Carrollton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →